DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE CONS, and when can generic versions of GLAXOSMITHKLINE CONS drugs launch?

GLAXOSMITHKLINE CONS has fifteen approved drugs.

There are eleven US patents protecting GLAXOSMITHKLINE CONS drugs.

There are three hundred and fifteen patent family members on GLAXOSMITHKLINE CONS drugs in forty-eight countries and eighteen supplementary protection certificates in eleven countries.

Summary for Glaxosmithkline Cons

International Patents:	315
US Patents:	11
Tradenames:	11
Ingredients:	10
NDAs:	15

Drugs and US Patents for Glaxosmithkline Cons

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SPRAY;TOPICAL	021124-002	Mar 17, 2000		OTC	Yes	Yes
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	8,147,461		Y
Glaxosmithkline Cons	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	021330-001	Oct 31, 2002		OTC	Yes	No
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000		OTC	Yes	Yes
Glaxosmithkline Cons	PREVACID 24 HR	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	022327-001	May 18, 2009		OTC	Yes	Yes
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	7,541,350		Y

Expired US Patents for Glaxosmithkline Cons

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Cons	EXCEDRIN (MIGRAINE)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998	4,943,565
Glaxosmithkline Cons	LAMISIL	terbinafine hydrochloride	SOLUTION;TOPICAL	020749-001	Oct 17, 1997	4,755,534*PED
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000	5,681,849*PED
Glaxosmithkline Cons	LAMISIL AT	terbinafine	GEL;TOPICAL	021958-001	Jul 24, 2006	5,856,355*PED
Glaxosmithkline Cons	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007	4,598,089
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SPRAY;TOPICAL	021124-002	Mar 17, 2000	6,121,314*PED

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	60 mg		2010-09-08
	Gum	4 mg		2013-01-22
	Gum	2 mg		2013-01-22

International Patents for Glaxosmithkline Cons Drugs

Country	Document Number	Estimated Expiration
South Korea	20050004845
Denmark	1305329
Slovenia	1775305
Japan	2007528248
European Patent Office	1699512
European Patent Office	1471884

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
6	Finland
C0014	France		PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
C/GB98/044	United Kingdom		PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
2008000029	Germany		PRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0343	Netherlands		300343, 20210803, EXPIRES: 20230110

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glaxo Grp England
• Glaxo Grp Ltd
• Glaxosmithkline
• Glaxosmithkline Con
• Glaxosmithkline Cons
• Glaxosmithkline Llc